The concern of generic competition has consistently loomed around copyright’s iconic drug, Viagra, sparking questions about the outlook of connected pharmaceutical stakes. While initial times saw impressive profits, the exclusivity lapse has created the path for cheaper alternatives, likely diminishing profitability and creating a genuine risk fo